To evaluate changes in hospital outcomes for infants with neonatal opioid withdrawal syndrome (NOWS) assessed by the Finnegan Tool before (10/1/2019 to 12/31/2019;pre-epoch) and after (7/1/2021 to 3/31/2022;post-epoch) publication of the 2020 AAP NOWS clinical report. This subgroup analysis included infants with NOWS assessed with the Finnegan Tool and enrolled in the INFORM NOW study (pre- and post-epoch 183 and 267 infants respectively). No differences were found between epochs in initiation or length of pharmacologic treatment(LOT), or length of stay(LOS). Outcomes were modified by opioid type: LOT was 20% shorter (aMR=0.80; 95%CI:0.69,0.93) and LOS was 16% shorter (aMR=0.84; 95%CI:0.73,0.96) for buprenorphine treated infants post- compared to pre-epoch, while LOT and LOS were longer in the post-epoch for those treated with methadone. There was no difference in outcomes before and after publication of the AAP report. However, the type of postnatal opioid did modify study results.
Devlin et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: